CRP and neoplasm: In our study, although patients with LRP1B mutation had higher bTMB, CRP, PD-L1 positive rate, and larger tumor size, the association of LRP1B mutation with improved outcomes to ICI plus chemotherapy remained consistent after controlling for these factors.